Global Dermatological Drugs Market 2014-2018

DUBLIN, April 28, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/3ldn2f/global) have announced the addition of the "Global Dermatological Drugs Market 2014-2018" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. 

Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics.

According to the report, one of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis.

Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. 

Key Topics Covered: 

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Market Segmentation by Type

08. Geographical Segmentation

09. Buying Criteria

10. Rate of Incidence and Prevalence

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

18. Key Vendor Analysis

19. Other Reports in this Series

Companies Mentioned:

• AbbVie Inc.
• Actavis plc
• Allergan Inc.
• Almirall SA
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Bristol Myers Squibb Co.
• Celgene Corp.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Galderma S.A.
• Genentech Inc.
• Incyte Corp.
• Isotechnika Inc.
• Johnson & Johnson Ltd.
• LEO Pharma A/S
• Merck & Co. Inc.
• Mylan Pharmaceuticals Inc.
• Novartis AG
• Pfizer Inc.
• Stiefel Laboratories Inc.
• UCB SA.
• Valeant Pharmaceuticals International Inc.

For more information visit http://www.researchandmarkets.com/research/3ldn2f/global

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

SOURCE Research and Markets